The Bridge vs. paying cash through NovoCare or LillyDirect
Short answer: If you're Bridge-eligible, $50/month beats every self-pay option by a wide margin — manufacturer direct-pay programs (Novo Nordisk's NovoCare pharmacy for Wegovy, Eli Lilly's LillyDirect for Zepbound) typically run several hundred dollars a month. Self-pay mainly matters for people who don't qualify for the Bridge or any coverage path.
Program facts last verified against CMS: July 21, 2026
What the self-pay programs are
Both major manufacturers sell direct to patients at cash prices well below retail — commonly in the several-hundred-dollars-per-month range, with pricing that has changed repeatedly and varies by product, dose, and form (Zepbound vials, for instance, have been priced below the pens). Check NovoCare and LillyDirect for current numbers rather than trusting any article's snapshot, including ours.
Even at their friendliest prices, self-pay costs roughly five to ten times the Bridge's $50. The comparison only becomes interesting if you're ineligible: BMI below the thresholds, no qualifying condition, no Medicare drug coverage — or after December 2027 if the program sunsets without replacement, when self-pay may become the fallback for everyone currently in it.
A caution on 'cheap' alternatives
Compounded semaglutide and tirzepatide — the sub-$200 offers widespread in recent years — are winding down: the FDA moved in 2026 to end bulk compounding of these molecules, and the era of legal mass-market compounded GLP-1s is effectively closing. Treat remaining cheap offers with real skepticism about source and quality, and see our full guide to the compounded question.
Your cost through the program
Bridge program: $600 total (12 × $50).
Typical manufacturer self-pay for the same months: roughly $4,200–$7,800 (check current NovoCare/LillyDirect pricing — it changes).
Estimated savings: $3,600+. See if you qualify →
Take the 2-minute eligibility check →
Common questions
Can I use self-pay and the Bridge together?
There's nothing to combine — the Bridge is a coverage program with a $50 copay; self-pay is buying outside coverage entirely. If you're Bridge-eligible, the Bridge is simply cheaper.
Why would a Medicare member ever self-pay?
Usually because they don't qualify: BMI below 27, no qualifying condition at their tier, or no Part D enrollment. Self-pay is also the likeliest fallback if the program ends after 2027.
Are manufacturer copay cards an option instead?
No — Medicare beneficiaries are generally excluded from manufacturer copay-card programs under federal rules. The direct-pay pharmacies are the manufacturers' Medicare-legal alternative.
Related
Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF